The Peptide CommonsEst. May 2024
Independent. We sell nothing and are affiliated with no manufacturer or pharmacy. Every moderation action is logged in public
Regional · European Union

[2026 update] EU-wide position versus national implementation

Solved
Solved by a.novak in post #2
I had written a reply contradicting the opening post and deleted it. Here is what survived. Anyone quoting an eligibility threshold should cite the national document, because thresholds differ between states and have changed within them. That is my reading. Someone else read the same page differently and was…

Jump to the accepted answer →

FI
f.ibarraTL219 Dec 2024#1

On the subject in the title: EU-wide position versus national implementation Working notes rather than a conclusion.

A methods question rather than a substantive one, about eu-wide position versus national implementation.

Everyone quotes the same figure and I cannot find anyone who says how it was arrived at. That is not an accusation; it usually means the derivation is somewhere obvious and I have missed it.

46 likes 19mo
AN
a.novakTL2 Solution30 Dec 2024#2

I had written a reply contradicting the opening post and deleted it. Here is what survived.

Anyone quoting an eligibility threshold should cite the national document, because thresholds differ between states and have changed within them.

That is my reading. Someone else read the same page differently and was reasonable.

7 likes 19mo
DT
d.tammTL27 Jan 2025#3

The centralised authorisation covers the union and national access decisions do not. That distinction accounts for most of the apparent contradictions in this subcategory.

1 like 19mo
Promoted into the documentation commons. The content of this topic is maintained at Access notes: New Zealand, with named maintainers and a review date. The promotion was discussed in doc review. Corrections are best raised against the document, which is the version that gets kept current.

Suggested topics

TopicParticipantsRepliesViewsActivity
German, French and Dutch differences, compared
German, French and Dutch differences, compared — setting out what I have, and where I think it stops being reliable. Asking about german directly, because I have read four threads on it and each answered a…
AKMMR 2 12k 10h
EMA product information as a primary source
Posting this under the heading it deserves: EMA product information as a primary source Everything below is what sits behind that. Something about EMA product information does not reconcile and I would like a…
YISVCDAMB+70 74 7k 8mo
Coming back to: Cross-border purchase rules within the EU
Cross-border purchase rules within the EU Writing it up because I had to work it out twice and would rather nobody else did. Cross-border purchase rules within — I have the observation and I do not trust my…
JEDBNRPFFE+12 16 2.8k 11mo
Revisiting: German, French and Dutch differences, compared
Posting this under the heading it deserves: Revisiting: German, French and Dutch differences, compared Everything below is what sits behind that. I have spent a fortnight trying to pin German down and I want…
ITKSTHEDS+90 99 32k 9mo
Reimbursement variation across member states
Reimbursement variation across member states Writing it up because I had to work it out twice and would rather nobody else did. Asking about reimbursement variation across member states directly, because I…
SFJSREBS+7 11 39k 3mo

Related topics — sharing the tags personal import, cost per milligram, formulary

TopicParticipantsRepliesViewsActivity
Price changes over 2025 and 2026, tabulated and dated — does this still hold?
Price changes over 2025 and 2026, tabulated and dated — does this still hold? I have a specific reason for asking rather than idle curiosity, and the context is below. Documenting an access outcome, dated,…
WMCCDFKSDO+147 156 18k 3mo
Coverage for the indication versus for the drug
Coverage for the indication versus for the drug — setting out what I have, and where I think it stops being reliable. The question about coverage that I actually want answered is the second one below. The…
AAAKEFHJG+70 79 18k 14mo
Prescription portability between countries
Prescription portability between countries — setting out what I have, and where I think it stops being reliable. Asking about prescription portability between countries directly, because I have read four…
SGTLDCIAL+104 114 6.1k 3h
Price changes over 2025 and 2026, tabulated and dated
Posting this under the heading it deserves: Price changes over 2025 and 2026, tabulated and dated Everything below is what sits behind that. Documenting an access outcome, dated, because everything in this…
MAOCASMIDB+4 8 658 14mo
Reimbursement variation across member states
Reimbursement variation across member states Writing it up because I had to work it out twice and would rather nobody else did. Asking about reimbursement variation across member states directly, because I…
SFJSREBS+7 11 39k 3mo